Solnasin Tablets 5mg (Solisphenacin Succinate)

Adult dose

The recommended dose for adults (including older adults) is 5mg once daily. If needed, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken with or without food and should be swallowed whole with water. Dosage adjustment is required for the following patients. 1. Patients with renal impairment: No dosage adjustment is needed in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily 2. Patients with hepatic impairment: No dosage adjustment is needed in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. 3. Patients receiving a strong cytochrome P450 3A4 (CYP3A4) inhibitor: Limit the maximum daily dose to 5mg in patients receiving ketoconazole or another strong CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole).

This medication should not be used in patients with urinary retention symptoms. Additionally, it can be risky for patients with severe gastrointestinal issues, myasthenia gravis, or narrow-angle glaucoma. It should also not be taken by individuals allergic to this medication or its components. Patients undergoing hemodialysis or with severely impaired liver and kidney function should avoid this medication. Those with genetic lactose intolerance should also avoid this medication as it contains lactose. Patients at risk of urinary obstruction or with slow gastrointestinal motility, and those with severe renal or liver impairment should use this medication cautiously. In particular, patients with moderate or severe liver function impairment or those taking CYP3A4 inhibitors may require dose adjustments. Patients on medications that could exacerbate gastroesophageal reflux or esophagitis should also be cautious. Side effects such as dry mouth, constipation, blurred vision, urinary retention, and dry eyes may occur. Among adverse reactions, dry mouth and constipation are the most common, and high doses may lead to severe gastrointestinal issues. Various symptoms such as dizziness, depression, cough, and hypertension have also been reported. This medication may increase the risk of cardiac arrhythmias in patients with QT prolongation syndrome or hyperkalemia, so caution is warranted. If severe allergic reactions such as angioedema or anaphylaxis occur, the medication should be stopped immediately, and treatment should be initiated. Additionally, this medication may affect the ability to drive or operate machinery, so caution is needed. When taken with other anticholinergic drugs, the effects may be enhanced or side effects may worsen, so consulting a healthcare professional is necessary. Safety in pregnant women has not been established, so it should be used cautiously during pregnancy, and during breastfeeding, it should be avoided as it may be secreted in breast milk and harm the newborn. Safety and efficacy in pediatric patients have not been confirmed, thus it should not be administered to children. In cases of overdose, symptoms may include headache, dry mouth, dizziness, drowsiness, and blurred vision, and appropriate emergency care, such as gastric lavage or activated charcoal, should be sought if necessary. Special caution is necessary for patients with impaired liver or kidney function, a history of heart disease, or those at risk of QT prolongation.

dry mouth, constipation, blurred vision, urinary retention, dry eyes, nausea, indigestion, upper abdominal pain, vomiting, urinary tract infection, influenza, pharyngitis, dizziness, depression, leg edema, fatigue, cough, hypertension, angioedema, fecal impaction, colonic obstruction, bowel obstruction, vascular edema, anaphylactic reaction, vomiting, gastroesophageal reflux disease, intestinal obstruction, peripheral edema, headache, hallucination, drowsiness, delirium, renal impairment, itching, rash, hives, vascular edema, erythema multiforme, exfoliative dermatitis, atrial fibrillation, palpitations, tachycardia, polymorphic ventricular tachycardia, QT interval prolongation on electrocardiogram, abnormal liver function tests, decreased appetite, hyperkalemia, speech disorder, glaucoma, muscle weakness, dysuria, decreased urinary flow, bladder neck obstruction, cystitis, rhinitis, urinary retention, increased serum creatinine, perforated duodenal ulcer, urinary incontinence, acute renal failure, bladder neck obstruction, worsening renal impairment, pneumonia, elevated prostate-specific antigen, ovarian carcinoma, bile duct cancer, uterine cancer, myocardial infarction, decreased cardiac output, soft tissue infection, frequency of urination, urinary disorder, urgency incontinence, neurogenic bladder, skin tingling, diarrhea, bloating, nocturia, reduced urine volume, urinary stones, urinary incontinence, sensory disturbance, gait difficulty, limb tremors, chest tightness, chest pain, periorbital edema, edema, benign prostatic hyperplasia, pruritus of the male genitalia, decreased libido, erectile dysfunction, abnormal orgasm, retrograde ejaculation, blood dyscrasia, keratosis, hair loss, feeling of sinking, anxiety, decreased sexual desire, back pain, vaginal bleeding, syncope, hearing impairment, thirst, erectile dysfunction, headache, dry mouth, drowsiness

This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly closed container. The storage temperature should be maintained between 1 degree and 30 degrees Celsius at room temperature. This way, the effectiveness of the medication can be maintained for a longer period.

Appearance

Bright yellow round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle, 100 tablets/PTP [(10 tablets/PTP x 10)]